Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago
🌐 বাংলায় দেখুন

Indications

Inflammatory Bowel Disease Rheumatoid Arthritis Eczema Inflammation

Upadacitinib is a Janus kinase (JAK) inhibitor. It is used to treat adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. It is also used in adults and children aged 2 years and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. For atopic dermatitis, it is used in adults and children aged 12 years and older with refractory, moderate to severe disease that is not adequately controlled with other systemic drug products, including biologics, or when those therapies are inadvisable. Upadacitinib is also used in adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. The same applies to adults with moderately to severely active Crohn's disease, and to adults with active ankylosing spondylitis. Adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation can also use it, if they have had an inadequate response or intolerance to TNF blocker therapy. Finally, it is used in patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Upadacitinib is a Janus kinase (JAK) inhibitor. JAKs are enzymes inside the cell. They pass on signals that arise when cytokines or growth factors bind to their receptors on the cell membrane, and in this way they influence haematopoiesis and the function of immune cells. Along this signalling pathway, JAKs phosphorylate and activate the Signal Transducers and Activators of Transcription (STATs), which modulate activity inside the cell, including gene expression. Upadacitinib acts on the pathway at the level of the JAKs, so it prevents the phosphorylation and activation of STATs.

Pregnancy & Breastfeeding

There isn't much human data on Upadacitinib in pregnant women, and what exists is not enough to tell whether the medicine raises the risk of major birth defects or miscarriage. Animal studies, though, show that upadacitinib could harm a developing baby. Women who are taking it should not breastfeed.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Upadacitinib is given at different doses depending on the condition. For rheumatoid arthritis, the dose is 15 mg once daily. In psoriatic arthritis, adults 18 years of age and older also take 15 mg once daily. For atopic dermatitis, patients in the 12 kg to 65 kg group (weighing at least 40 kg) start with 15 mg once daily. If the response is not adequate, the dose may be increased to 30 mg once daily, and the medicine should be stopped if an adequate response is still not achieved at 30 mg. Adults 65 years of age and older take 15 mg once daily. In adult patients with ulcerative colitis, the induction dose is 45 mg once daily for 8 weeks, followed by a maintenance dose of 15 mg once daily. A dose of 30 mg once daily may be considered for patients with refractory, severe or extensive disease, and the medicine should be discontinued if an adequate therapeutic response is not achieved with 30 mg. Adult patients with Crohn's disease take 45 mg once daily for 12 weeks as induction, then 15 mg once daily for maintenance. Here too, 30 mg once daily may be considered for refractory, severe or extensive disease, and treatment should be discontinued if 30 mg does not give an adequate therapeutic response. For ankylosing spondylitis, the dose is 15 mg once daily. For non-radiographic axial spondyloarthritis, it is also 15 mg once daily. In polyarticular juvenile idiopathic arthritis, patients weighing 30 kg and greater take 15 mg once daily.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.